STAT+: A ‘conditional’ EUA for a CytoDyn Covid treatment? FDA says no such thing exists
Speaking Monday night to investors on a conference call, CytoDyn CEO Nader Pourhassan said the company had requested a “conditional” emergency use authorization from the Food and Drug Administration for an experimental Covid-19 antibody treatment, despite its failure in a late-stage clinical trial.
But a “conditional” EUA — as described by CytoDyn’s CEO — does not exist.
